Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Abstract
A new, safe, and effective vaccine against poliovirus is urgently needed not only to complete the eradication of the virus but also to be used in the future to prevent possible virus reemergence in a postpolio world. Currently, new formulations of the oral vaccine, as well as improvements to the inactivated vaccine, are being explored. In this study, we designed a viral vector with mucosal tropism that expresses poliovirus capsid proteins. Thus, poliovirus VLPs are produced in vivo , in the cells of a vaccine recipient, and are presented to the immune system in the context of vector virus replication, stimulating the development of systemic and mucosal immune responses. Such an approach allows the development of an affordable and safe vaccine that does not rely on the full-length poliovirus genome at any stage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In recent years, PV VLPs with native antigenicity have been produced in various systems, including mammalian cells, plants, insects, bacteria and yeast [129,131,132,133,134,135,136].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [129]
Citations
Cites
2 retracted
Khattar, S. K., Samal, S., DeVico, A. L., Collins, P. L., & Samal, S. K. (2011) · Journal of Virology · doi:10.1128/jvi.05050-11 · Cited by 37 · cited 1×
“Previous research indicates that the immune response of guinea pigs to NDV vector-based vaccines resembles that observed in primate models (31, 38, 39).”
ResultSelf-citationRetractedExperimental infection of hamsters with avian paramyxovirus serotypes 1 to 9
Samuel, A. S., Subbiah, M., Shive, H. R., Collins, P. L., & Samal, S. K. (2011) · Veterinary Research · doi:10.1186/1297-9716-42-38 · Cited by 36 · cited 1×
“Rabbit polyclonal antibodies against NDV NP protein have been described previously (74), and mouse monoclonal antibodies against NDV HN were a kind gift from Shin-Hee Kim (University of Maryland).”
MethodSelf-citationRetractedBradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“Prior to the antibody assay and microneutralization test, the protein concentrations of vaginal wash samples were determined by the Bradford protocol (76).”
MethodGuide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche
Kärber, G. (1931) · Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie · doi:10.1007/bf01863914 · Cited by 3,104 · cited 1×
“Poliovirus type 1 Mahoney was propagated in HeLa cells, and the viral titer was either determined by a plaque assay and expressed as PFU per milliliter (for experiments where expression of poliovirus proteins was assessed) or determined by the terminal dilution method and expressed as 50% tissue culture infective dose…”
MethodGuide for the Care and Use of Laboratory Animals (8th edn)
Albus, U. (2012) · Laboratory Animals · doi:10.1258/la.2012.150312 · Cited by 1,693
Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., Carroll, M. W., Dean, N. E., Diatta, I., Doumbia, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32621-6 · Cited by 1,110
Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme
Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.016 · Cited by 407 · cited 1×
“Moreover, NDV has been explored as an oncolytic virus and demonstrated an excellent safety profile in clinical trials, even when high doses of the virus were administered intravenously to individuals with compromised immune systems (30).”
BackgroundImmunoglobulin Responses at the Mucosal Interface
Cerutti, A., Chen, K., & Chorny, A. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101317 · Cited by 395
Garbutt, M., Liebscher, R., Wahl-Jensen, V., Jones, S., Möller, P., Wagner, R., Volchkov, V., Klenk, H.-D., Feldmann, H., & Ströher, U. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5458-5465.2004 · Cited by 381 · cited 1×
“The recent rapid deployment and success of a vesicular stomatitis virus (VSV)-based vectored vaccine against Ebola virus demonstrates that such an approach to vaccine evaluation is warranted and proves the clinical relevance of a vectored vaccine with a design similar to that described in this study (67, 68).”
MethodRationalizing the development of live attenuated virus vaccines
Lauring, A. S., Jones, J. O., & Andino, R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1635 · Cited by 328
Protein 3CD is the major poliovirus proteinase responsible for cleavage of the p1 capsid precursor
Ypma-Wong, M. F., Dewalt, P. G., Johnson, V. H., Lamb, J. G., & Semler, B. L. (1988) · Virology · doi:10.1016/0042-6822(88)90172-9 · Cited by 326 · cited 1×
“Poliovirus is a nonenveloped virus, and its capsid proteins are produced by the processing of the capsid protein precursor P1 by the viral protease 3CD (15).”
BackgroundOne hundred years of poliovirus pathogenesis
Racaniello, V. R. (2006) · Virology · doi:10.1016/j.virol.2005.09.015 · Cited by 322 · cited 1×
“Its replication in motor neurons may induce a spectrum of neurological symptoms, from temporary weakness to permanent paralysis of limbs and muscles controlling breathing, occasionally leading to death (1).”
BackgroundEngineering attenuated virus vaccines by controlling replication fidelity
Vignuzzi, M., Wendt, E., & Andino, R. (2008) · Nature Medicine · doi:10.1038/nm1726 · Cited by 282
Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses
Chare, E. R., Gould, E. A., & Holmes, E. C. (2003) · Journal of General Virology · doi:10.1099/vir.0.19277-0 · Cited by 274 · cited 1×
“An important property of the viruses of the order Mononegavirales, which includes NDV, is the virtual nonexistence of recombination, leading to much higher genome stability than that of other groups of RNA viruses (63, 64).”
BackgroundKapczynski, D. R., & King, D. J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.140 · Cited by 263 · cited 1×
“In this study, we utilized the nonpathogenic LaSota strain of NDV, which is broadly used as a live vaccine in the poultry industry and has never been documented to develop a pathogenic phenotype (61, 62).”
MethodRecombinant Newcastle Disease Virus as a Vaccine Vector
Nakaya, T., Cros, J., Park, M.-S., Nakaya, Y., Zheng, H., Sagrera, A., Villar, E., Garcı́a-Sastre, A., & Palese, P. (2001) · Journal of Virology · doi:10.1128/jvi.75.23.11868-11873.2001 · Cited by 250
Immunology of gut mucosal vaccines
Pasetti, M. F., Simon, J. K., Sztein, M. B., & Levine, M. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00970.x · Cited by 248 · cited 1×
“However, we observed accumulation of antipoliovirus IgM and IgA antibodies in the blood serum, as well as antipoliovirus neutralizing and specific IgG antibodies in vaginal wash samples, strongly indicative of the development of a protective mucosal immune response (45).”
BackgroundEl‐Kamary, S. S., Pasetti, M. F., Mendelman, P. M., Frey, S. E., Bernstein, D. I., Treanor, J. J., Ferreira, J., Chen, W. H., Sublett, R., Richardson, C., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/657087 · Cited by 226
Basavappa, R., Filman, D. J., Syed, R., Flore, O., Icenogle, J. P., & Hogle, J. M. (1994) · Protein Science · doi:10.1002/pro.5560031005 · Cited by 209 · cited 1×
“are unstable and easily convert from a protective D-antigen to an inactivated C- or H-antigen conformation, which does not induce neutralizing antibodies (21).”
BackgroundVaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication
Minor, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.071 · Cited by 183 · cited 1×
“These vaccine-derived polioviruses (VDPV) can establish circulation in human populations and have caused numerous outbreaks of paralytic poliomyelitis (5, 6).”
BackgroundMacLennan, C., Dunn, G., Huissoon, A. P., Kumararatne, D. S., Martin, J., O'Leary, P., Thompson, R. A., Osman, H., Wood, P., Minor, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16150-3 · Cited by 162
A Common Mucosal Immunologic System Involving the Bronchus, Breast and Bowel
Bienenstock, J., McDermott, M., Befus, D., & O’Neill, M. (1978) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4684-3369-2_7 · Cited by 161 · cited 1×
“The mucosal membranes in the body are involved in constant immunological communication and, in many cases, may be considered a unified immunological site (53).”
BackgroundA Critical Role of a Cellular Membrane Traffic Protein in Poliovirus RNA Replication
Belov, G. A., Feng, Q., Nikovics, K., Jackson, C. L., & Ehrenfeld, E. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000216 · Cited by 151 · cited 1×
“The poliovirus replicon replication assay was performed essentially as described previously (75), except that instead of being transfected with replicon RNA, HeLa cells were infected with replicon RNA trans-encapsidated in poliovirus capsid proteins expressed during the replication of the recombinant virus NDV-polio.”
MethodSelf-citationPoliovirus Requires a Precise 5′ End for Efficient Positive-Strand RNA Synthesis
Herold, J., & Andino, R. (2000) · Journal of Virology · doi:10.1128/jvi.74.14.6394-6400.2000 · Cited by 149
Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines
Kim, S., & Samal, S. K. (2016) · Viruses · doi:10.3390/v8070183 · Cited by 146 · cited 1×
“There is no preexisting immunity to NDV in the human population, and its replication in human hosts is safe and self-limiting (24, 25).”
BackgroundSelf-citationPolio eradication: the OPV paradox
Dowdle, W. R., De Gourville, E., Kew, O. M., Pallansch, M. A., & Wood, D. J. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.401 · Cited by 144
Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract
Ruane, D., Brane, L., Reis, B. S., Cheong, C., Poles, J., Do, Y., Zhu, H., Velinzon, K., Choi, J.-H., Studt, N., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122762 · Cited by 139
DiNapoli, J. M., Kotelkin, A., Yang, L., Elankumaran, S., Murphy, B. R., Samal, S. K., Collins, P. L., & Bukreyev, A. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703584104 · Cited by 136
Self-citationBukreyev, A. A., Huang, Z., Yang, L., Elankumaran, S., Claire, M. S., Murphy, B. R., Samal, S. K., & Collins, P. L. (2005) · Journal of Virology · doi:10.1128/jvi.79.21.13275-13284.2005 · Cited by 132 · cited 1×
“Previous research indicates that the immune response of guinea pigs to NDV vector-based vaccines resembles that observed in primate models (31, 38, 39).”
ResultSelf-citationThe Evolutionary Pathway to Virulence of an RNA Virus
Stern, A., Yeh, M. T., Zinger, T., Smith, M., Wright, C., Ling, G., Nielsen, R., Macadam, A., & Andino, R. (2017) · Cell · doi:10.1016/j.cell.2017.03.013 · Cited by 127 · cited 1×
“Second, replicating viruses rapidly lose attenuating mutations and undergo recombination with other enteroviruses, thus regaining a neuropathological phenotype indistinguishable from that of wt polioviruses (3, 4).”
BackgroundHomologous Recombination in Negative Sense RNA Viruses
Han, G., & Worobey, M. (2011) · Viruses · doi:10.3390/v3081358 · Cited by 121 · cited 1×
“An important property of the viruses of the order Mononegavirales, which includes NDV, is the virtual nonexistence of recombination, leading to much higher genome stability than that of other groups of RNA viruses (63, 64).”
BackgroundGrimwood, K., Lund, J. C., Coulson, B. S., Hudson, I. L., Bishop, R. F., & BARNES, G. L. (1988) · Journal of Clinical Microbiology · doi:10.1128/jcm.26.4.732-738.1988 · Cited by 116
Hummeler, K., Anderson, T. F., & Brown, R. A. (1962) · Virology · doi:10.1016/0042-6822(62)90205-2 · Cited by 111
Dunn, G., Klapsa, D., Wilton, T., Stone, L., Minor, P. D., & Martin, J. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005114 · Cited by 106
(1997) · PsycEXTRA Dataset · doi:10.1037/e547562006-001 · Cited by 105
Sharma, R. D., Raychaudhuri, S., & Dasgupta, A. (2004) · Virology · doi:10.1016/j.virol.2003.10.020 · Cited by 101 · cited 1×
“This design was chosen to provide a high level of expression of the structural protein precursor P1 and a relatively low level of expression of 3CD protease, minimizing its possible toxic effect on cellular metabolism (32).”
BackgroundHuang, Z., Krishnamurthy, S., Panda, A., & Samal, S. K. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-7-1729 · Cited by 100
Self-citationDiNapoli, J. M., Yang, L., Suguitan, A. L., Elankumaran, S., Dorward, D. W., Murphy, B. R., Samal, S. K., Collins, P. L., & Bukreyev, A. A. (2007) · Journal of Virology · doi:10.1128/jvi.00713-07 · Cited by 100
Self-citationDiNapoli, J. M., Nayak, B., Yang, L., Finneyfrock, B. W., Cook, A., Andersen, H., Torres-Velez, F. J., Murphy, B. R., Samal, S. K., Collins, P. L., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01946-09 · Cited by 99
Self-citationUrakawa, T., Ferguson, M., Minor, P. D., Cooper, J., Sullivan, M., Almond, J. W., & Bishop, D. H. L. (1989) · Journal of General Virology · doi:10.1099/0022-1317-70-6-1453 · Cited by 97
Panda, A., Elankumaran, S., Krishnamurthy, S., Huang, Z., & Samal, S. K. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.4965-4975.2004 · Cited by 87
Self-citationDiNapoli, J. M., Yang, L., Samal, S. K., Murphy, B. R., Collins, P. L., & Bukreyev, A. A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.024 · Cited by 86
Self-citationRamírez, K., Wahid, R., Richardson, C., Bargatze, R. F., El‐Kamary, S. S., Sztein, M. B., & Pasetti, M. F. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.05.006 · Cited by 80
Shulman, L. M., Gavrilin, E., Jorba, J., Martin, J., Burns, C. C., Manor, Y., Moran-Gilad, J., Sofer, D., Hindiyeh, M. Y., Gamzu, R., et al. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.7.20709 · Cited by 79
Simonyan, V. V., Chumakov, K., Dingerdissen, H., Faison, W. J., Goldweber, S., Golikov, A., Gulzar, N., Karagiannis, K., Lam, P. V. N., Maudru, T., et al. (2016) · Database · doi:10.1093/database/baw022 · Cited by 78
Self-citationRecombinant Newcastle disease virus as a vaccine vector
Huang, Z., Elankumaran, S., Panda, A., & Sk, S. (2003) · Poultry Science · doi:10.1093/ps/82.6.899 · Cited by 75 · cited 1×
“The advantage of APMVs as vectors is that there are at least 15 APMV types with properties similar to those of NDV (APMV type 1) that are not pathogenic to poultry and can be explored as backbones for vectored vaccines (65, 66).”
BackgroundOhka, S., Igarashi, H., Nagata, N., Sakai, M., Koike, S., Nochi, T., Kiyono, H., & Nomoto, A. (2007) · Journal of Virology · doi:10.1128/jvi.02675-06 · Cited by 74 · cited 1×
“While mice expressing poliovirus receptor are available, they are susceptible to oral poliovirus infection, necessary for evaluation of the development of gut mucosal immunity, only in the background of alpha/beta interferon receptor knockout; thus, their immune response to vaccination cannot be informative (51).”
BackgroundBräutigam, S., Snezhkov, E., & Bishop, D. H. L. (1993) · Virology · doi:10.1006/viro.1993.1067 · Cited by 72
Cochi, S. L., Hegg, L., Kaur, A., Pandak, C., & Jafari, H. S. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1104 · Cited by 71 · cited 1×
“The success of the Global Polio Eradication Initiative, which brought down the number of poliovirus-induced cases of paralysis from 380,000 in 1988, when it started, to 50 in 2016 (2), is due to an oral poliovirus vaccine (OPV).”
BackgroundIncreasing Type 1 Poliovirus Capsid Stability by Thermal Selection
Adeyemi, O. O., Nicol, C., Stonehouse, N. J., & Rowlands, D. J. (2016) · Journal of Virology · doi:10.1128/jvi.01586-16 · Cited by 67 · cited 1×
“processes and face significant problems of stabilizing labile poliovirus epitopes required for the induction of protective neutralizing antibodies (22, 47, 48).”
BackgroundActivation of Cellular Arf GTPases by Poliovirus Protein 3CD Correlates with Virus Replication
Belov, G. A., Habbersett, C., Franco, D., & Ehrenfeld, E. (2007) · Journal of Virology · doi:10.1128/jvi.00840-07 · Cited by 66
Self-citationPoliovirus replication requires the N-terminus but not the catalytic Sec7 domain of ArfGEF GBF1
Belov, G. A., Kovtunovych, G., Jackson, C. L., & Ehrenfeld, E. (2010) · Cellular Microbiology · doi:10.1111/j.1462-5822.2010.01482.x · Cited by 64
Self-citationAnsardi, D. C., Porter, D. C., & Morrow, C. D. (1991) · Journal of Virology · doi:10.1128/jvi.65.4.2088-2092.1991 · Cited by 64
Yang, H., Zhao, J., Xue, J., Yang, Y., & Zhang, G. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.11.048 · Cited by 64 · cited 1×
“In this study, we utilized the nonpathogenic LaSota strain of NDV, which is broadly used as a live vaccine in the poultry industry and has never been documented to develop a pathogenic phenotype (61, 62).”
MethodFox, H., Knowlson, S., Minor, P. D., & Macadam, A. J. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006117 · Cited by 60
Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan
Shimizu, H. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.11.015 · Cited by 57 · cited 1×
“processes and face significant problems of stabilizing labile poliovirus epitopes required for the induction of protective neutralizing antibodies (22, 47, 48).”
BackgroundCross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor
Chen, Z., Fischer, E. R., Kouiavskaia, D., Hansen, B. T., Ludtke, S. J., Bidzhieva, B., Makiya, M., Agulto, L., Purcell, R. H., & Chumakov, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320041110 · Cited by 55 · cited 1×
“They were recognized by antibody A12, which binds a conformational epitope present only in functional virions (33, 34); they were able to trans-encapsidate a replicon RNA into functional virions; and most importantly, they were capable of inducing a neutralizing antibody response (see below).”
BackgroundSelf-citationLessons from a Public Health Emergency — Importation of Wild Poliovirus to Israel
Kopel, E., Kaliner, E., & Grotto, I. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1406250 · Cited by 53 · cited 1×
“To stop virus transmission, a mass vaccination campaign using live poliovirus vaccine had to be reimplemented, effectively reversing the poliovirus eradication strategy (50).”
MethodPfister, T., Pasamontes, L., Troxler, M., Egger, D., & Bienz, K. (1992) · Virology · doi:10.1016/0042-6822(92)90522-q · Cited by 47
Chen, Z., Chumakov, K., Dragunsky, E. M., Kouiavskaia, D. V., Makiya, M. A., Neverov, A., Rezapkin, G. V., Sebrell, A., & Purcell, R. H. (2011) · Journal of Virology · doi:10.1128/jvi.02553-10 · Cited by 46 · cited 1×
“They were recognized by antibody A12, which binds a conformational epitope present only in functional virions (33, 34); they were able to trans-encapsidate a replicon RNA into functional virions; and most importantly, they were capable of inducing a neutralizing antibody response (see below).”
BackgroundSelf-citationAddressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future
Patel, M. M., & Cochi, S. L. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix117 · Cited by 46 · cited 1×
“To circumvent the negative consequences of live vaccine while maintaining an adequate level of population protection, the road map of the eradication campaign calls for the cessation of live-vaccine use and a global switch to an inactivated poliovirus vaccine (IPV) by 2020 (12, 13).”
BackgroundPorter, D. C., Ansardi, D. C., Wang, J., McPherson, S. A., Moldoveanu, Z., & Morrow, C. D. (1998) · Virology · doi:10.1006/viro.1998.9046 · Cited by 45
Determining the Stage of the Estrous Cycle in Female Mice by Vaginal SmearPreprint
Gonzalez, G. (2016) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot094474 · Cited by 42 · cited 1×
“Some vaginal wash samples contained very little protein, likely because of an estrous cycle stage (46), and were excluded from the analysis.”
BackgroundPanyasing, Y., Goodell, C. K., Gimenez-Lirola, L. G., Kittawornrat, A., Wang, C., Schwartz, K., & Zimmerman, J. J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.10.040 · Cited by 40
Ciabattini, A., Pettini, E., Arsenijevic, S., Pozzi, G., & Medaglini, D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.11.021 · Cited by 35
Khattar, S. K., Manoharan, V. K., Bhattarai, B., LaBranche, C. C., Montefiori, D. C., & Samal, S. K. (2015) · mBio · doi:10.1128/mbio.01005-15 · Cited by 31 · cited 1×
“Previous research indicates that the immune response of guinea pigs to NDV vector-based vaccines resembles that observed in primate models (31, 38, 39).”
ResultSelf-citationHUMAN INFECTION WITH THE NEWCASTLE VIRUS OF FOWLS
KEENEY, A. H., & HUNTER, M. C. (1950) · Archives of Ophthalmology · doi:10.1001/archopht.1950.00910020583009 · Cited by 24
Pathogenicity and Immunology of Newcastle Disease Virus (NVD) in Man
Evans, A. S. (1955) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.45.6.742 · Cited by 16
Khattar, S. K., DeVico, A. L., LaBranche, C. C., Panda, A., Montefiori, D. C., & Samal, S. K. (2015) · Journal of Virology · doi:10.1128/jvi.02847-15 · Cited by 14 · cited 1×
“show any adverse effects associated with immunization, as was observed previously even for multiple cycles of administration of NDV-based vaccines (40).”
BackgroundSelf-citationFahmy, K., Hampton, L. M., Langar, H., Patel, M. M., Mir, T., Soloman, C., Hasman, A., Yusuf, N., & Teleb, N. A. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix133 · Cited by 14 · cited 1×
“To circumvent the negative consequences of live vaccine while maintaining an adequate level of population protection, the road map of the eradication campaign calls for the cessation of live-vaccine use and a global switch to an inactivated poliovirus vaccine (IPV) by 2020 (12, 13).”
BackgroundA case of human infection with Newcastle disease virus.
Mustaffa‐Babjee, A., Ibrahim, A. L., & Khim., T. S. (1976) · PubMed · Cited by 12
Weil, M., Shulman, L. M., Heiman, S., Stauber, T., Alfandari, J., Weiss, L., Silberstein, I., Indenbaum, V., Mendelson, E., & Sofer, D. (2016) · Eurosurveillance · doi:10.2807/1560-7917.es.2016.21.47.30408 · Cited by 12
Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived
Sutter, R. W., Okayasu, H., & Kiény, M.-P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix116 · Cited by 10 · cited 1×
“neutralizing antibodies during the long inactivation process (14).”
BackgroundA Transgenic Mouse Model of Poliomyelitis
Koike, S., & Nagata, N. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3292-4_7 · Cited by 9 · cited 1×
“Mice expressing poliovirus receptor in the wt background can be infected with poliovirus only via intramuscular inoculation, intraperitoneal inoculation, or direct inoculation into the central nervous system and essentially allow measurement of neutralizing antibody in the serum, a parameter that can be quantitatively…”
MethodUpdate on vaccine-derived polioviruses detected worldwide, April 2011–June 2012.
(2012) · PubMed · Cited by 8
COLLEGE OF PHYSICIANS OF PHILADELPHIA, SECTION ON OPHTHALMOLOGY
Fry, W., & Kauffman, M. L. (1951) · Archives of Ophthalmology · doi:10.1001/archopht.1951.01700020099011 · Cited by 1
Research works printed but not linked: 3
- Lamb RA, Parks GD. 2007. Paramyxoviridae: the viruses and their replication, p 1449–1496. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
- Samal SK. 2011. The biology of paramyxoviruses, p 69–114. Caister Academic Press, Norfolk, United Kingdom.
- . 1997. Manual for the virological investigation of polio. World Health Organization, Geneva, Switzerland.
Cited by
McCann, N. S., O’Connor, D., Lambe, T., & Pollard, A. J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102210 · Cited by 146
Hu, Z., Ni, J., Cao, Y., & Liu, X. (2020) · Vaccines · doi:10.3390/vaccines8020222 · Cited by 62
“Two human vaccine candidates based on NDV against poliovirus and Japanese encephalitis virus were generated and these vaccines were immunogenic in animal models [91,95].”
BackgroundViruses as tools in gene therapy, vaccine development, and cancer treatment
bin Umair, M., Fujimura, N. A., Kashif, H., Seerat-e-Fatima, Butt, F., Azhar, M., Munir, I., Ahmed, M. I., Khalil, W., Sharyar, H., et al. (2022) · Archives of Virology · doi:10.1007/s00705-022-05432-8 · Cited by 54
“Another study demonstrated the stimulation of host immunity against poliomyelitis virus by injection with rNDV expressing the poliovirus precursor capsid protein and the associated protease [162].”
BackgroundFulber, J. P. C., & Kamen, A. (2022) · Viruses · doi:10.3390/v14050975 · Cited by 37
“Vaccine Type Pathogen Disease Antigen Expressed Animal Model Production Platform * Route * Dose * Reference Live LaSota strain H7N9, H5N1 Respiratory infection HA Chicken ECEs im, on two doses of 5 × 106 PFU [128] Live LaSota strain VSV Vesicular stomatitis G Mouse ECEs im two doses of 1 × 107 TCID50 [129] Live LaSota…”
BackgroundInfluentialThe Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
Metadata
- Authors
- Viktorova, E. G., Khattar, S. K., Kouiavskaia, D., Laassri, M., Zagorodnyaya, T., Dragunsky, E., Samal, S., Chumakov, K., & Belov, G. A.
- Affiliations
- Virginia–Maryland College of Veterinary Medicine (US)
- Center for Biologics Evaluation and Research (US)
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2018-09
- Volume
- 92
- Issue
- 17
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC6096817
- OpenAlex
- W2808156154
- Cited by
- 29
- References
- 78
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 2 · 2022: 10 · 2021: 1 · 2020: 4
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (R21AI15383A)
- Topics
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- Newcastle disease virus vector, polio vaccine, poliovirus, virus-like particles, capsid protein, mucosal immunity, systemic immune response, live attenuated vaccine, vaccine safety
- MeSH terms
- Animals, Antibodies, Viral, Genetic Vectors, Guinea Pigs, Immunoglobulin A, Immunoglobulin G, Newcastle disease virus, Poliomyelitis, Poliovirus Vaccine, Inactivated, Vaccination, Poliovirus, Immunity, Mucosal, Poliovirus Vaccines, Capsid Proteins, Vaccines, Virus-Like Particle, Vaccines, Live, Unattenuated
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.